Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin + Saxagliptin for BBIT to BOT Reversal in T2D
NCT02965443Phase 4Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Feb 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin and saxagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Percentage of subjects achieving a HbA1c <= 7.5% and having a reversal from a BBIT to a BOT regimen at 24 weeks. Started Feb 2018; status: terminated.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02965443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965443.